Breath-Actuated Nebulizers for Asthma and Chronic Obstructive Pulmonary Disease Exacerbation: A Monte Carlo Simulation Demonstrating National Cost Savings and Length of Stay Reduction
BAN may yield significant cost savings driven primarily by a decreased likelihood of admission for COPD exacerbation. Further research is needed to validate clinical efficacy and address barriers to adoption.
Authors
- Da’Marcus E. Baymon
- Joshua J. Baugh (ORCID: https://orcid.org/0000-0003-0685-7331)
- Andrew Luo (ORCID: https://orcid.org/0000-0002-8367-7185)
- Gregory A. Peters (ORCID: https://orcid.org/0000-0001-6914-7316)
- Lauren M. Nentwich
- Christopher W. Baugh (ORCID: https://orcid.org/0000-0002-2360-1891)
- Joshua M. Kosowsky (ORCID: https://orcid.org/0000-0003-4891-6598)
Institutions
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Journal of the American College of Emergency Physicians Open
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.acepjo.2025.100112
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.52